利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

135 条记录 (耗时 0.044 秒)

    Substances
    5.
    发明申请
    Substances 审中-公开
    物质

    公开(公告)号：US20040146505A1

    公开(公告)日：2004-07-29

    申请号：US10470045

    申请日：2004-01-21

    发明人： Linda Gillian Durrant ,  Tina Parsons ,  Adrian Robins

    IPC分类号： A61K039/395 ,  C07K016/44

    CPC分类号： C07K16/4266 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/53 ,  C07K16/00 ,  C07K2317/52 ,  C07K2317/74 ,  Y10S530/806

    摘要： The invention relates to the use of a polypeptide which comprises i) a first portion comprising the part of human Fc which binds to CD64, and ii) a second portion comprising one or more heterologous T cell epitopes for stimulating a cytotoxic T cell response. The polypeptide may be an antibody which may be used to stimulate an cytotoxic T cell response against pathogens and tumour cells in patients in need of such treatment.

    摘要翻译： 本发明涉及多肽的用途，其包括i）包含结合CD64的人Fc部分的第一部分，和ii）包含刺激细胞毒性T细胞应答的一个或多个异源T细胞表位的第二部分。 多肽可以是可以用于刺激需要这种治疗的患者中针对病原体和肿瘤细胞的细胞毒性T细胞应答的抗体。

    Thrombopoietin(tpo) synthebody for stimulation of platelet production
    6.
    发明申请
    Thrombopoietin(tpo) synthebody for stimulation of platelet production 审中-公开
    血小板生成素（tpo）合成物，用于刺激血小板生成

    公开(公告)号：US20040136980A1

    公开(公告)日：2004-07-15

    申请号：US10469124

    申请日：2003-08-25

    发明人： Daniel A Soltis ,  Ronald M. Burch ,  Robert A. Ogert

    IPC分类号： A61K039/395 ,  C07K016/44

    CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/56

    摘要： The present invention relates to a synthetic variable region of an immunoglobin construct which contains in at least one of its CDRs a sequence of thrombopoietin, e.g. , IEGPTLRQWLAARA or its derivatives. This construct can efficiently bind and activate a thrombopoientin receptor (MPL) leading to stimulation of proliferation, growth or differentiation or modulation of apoptosis of hematopoietic cells, especially platelet progenitor cells. The invention further relates to the use of the synthebody to treat hematopoietic or immune disorders, and particularly thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions.

    摘要翻译： 本发明涉及免疫球蛋白构建体的合成可变区，其在至少一个CDR中含有血小板生成素例如IEGPTLRQWLAARA或其衍生物的序列。 该构建体可有效地结合和激活血小板生成素受体（MPL），导致刺激造血细胞，特别是血小板祖细胞的增殖，生长或分化或调节凋亡。 本发明还涉及合成物治疗造血或免疫疾病，特别是化疗，放射治疗或骨髓输血引起的血小板减少症的用途。

    Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
    10.
    发明申请
    Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof 审中-公开
    治疗性抗BGP（C-CAM1）抗体及其用途

    公开(公告)号：US20040047858A1

    公开(公告)日：2004-03-11

    申请号：US10241369

    申请日：2002-09-11

    发明人： Richard S. Blumberg ,  Atul Bhan

    IPC分类号： A61K039/395 ,  C07K016/42 ,  C07K016/44 ,  C12P021/02 ,  C12N005/06

    CPC分类号： C07K16/2803 ,  A61K2039/505

    摘要： Provided are specific antibodies which are capable of modulating T cell activity and uses thereof. In particular, antibodies and binding fragments thereof are described, which react with a specific domain of biliary glycoprotein (BGP), also known as CD66a, CEACAM1 and C-CAM1, and which are capable of suppressing the cytolytic activity of intestinal intraepithelial lymphocytes (iIELs). Furthermore, compositions comprising said antibodies are provided and methods of modulating immune cell proliferation, and treating immune response related diseases.

    摘要翻译： 提供能够调节T细胞活性的特异性抗体及其应用。 特别地，描述了抗体及其结合片段，其与胆素糖蛋白（BGP）的特异性结构域（也称为CD66a，CEACAM1和C-CAM1）反应，并且能够抑制肠上皮内淋巴细胞（iIEL）的细胞溶解活性 ）。 此外，提供了包含所述抗体的组合物和调节免疫细胞增殖以及治疗免疫应答相关疾病的方法。